Tutorial
These icons indicate there is something to be interacted with. Click it when you see it.
Poll
What are you most interested in learning about from ongoing clinical trials?
Tutorial
These icons indicate there is something to be interacted with. Click it when you see it.
Poll
Which of the following treatments is most likely to change your clinical practice?
Tutorial
These icons indicate there is something to be interacted with. Click it when you see it.
Poll
Which is the most important area for research in late-stage EGFR-mutant NSCLC?
Tutorial
These icons indicate there is something to be interacted with. Click it when you see it.
Poll
What are you most interested in learning about from ongoing clinical trials?
Tutorial
These icons indicate there is something to be interacted with. Click it when you see it.
Poll
Which of the following treatments is most likely to change your clinical practice?
Tutorial
These icons indicate there is something to be interacted with. Click it when you see it.
Poll
Which is the most important area for research in late-stage EGFR-mutant NSCLC?
Tutorial
These icons indicate there is something to be interacted with. Click it when you see it.
Poll
What are you most interested in learning about from ongoing clinical trials?
Tutorial
These icons indicate there is something to be interacted with. Click it when you see it.
Poll
Which of the following treatments is most likely to change your clinical practice?
Tutorial
These icons indicate there is something to be interacted with. Click it when you see it.
Poll
Which is the most important area for research in late-stage EGFR-mutant NSCLC?
touchCLINICAL PERSPECTIVES
A modular programme that includes a variety of interviews with experts and a patient, as well as downloadable resources. Close
- Share this Activity
- CE/CME Accredited
Perspectives on EGFR-mutant and wildtype NSCLC: Tailoring treatment advances in late-stage disease
Claim Credit-
PART 1 of 9 Skip to Modules
- Time: 08:53
Part 1 ć¼ EGFR-mutant NSCLC: Navigating the horizon in EGFR-mutant NSCLC
Dr Helena Yu, course director and thoracic oncologist, discusses the unmet needs of patients with EGFR-mutant metastatic non-small cell lung cancer (NSCLC) by highlighting the current challenges, areas for further research and clinical trial landscape.
After watching this activity, participants should be better able to:
- Recall the latest clinical trial data for first- and second-line treatment options in patients with EGFR-mutant and wildtype NSCLC and their implications for treatment sequencing.
This activity is jointly provided by USF Health and touchIME. read more
Target Audience
This activity has been designed to meet the educational needs of oncologists, including lung cancer specialists, pulmonologists, pathologists and oncology nurses involved in the management of patients with NSCLC.
Disclosures
USF Health adheres to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant relationships are listed below. All individuals not listed have no relevant financial relationships.
Faculty
Dr Helena Yu discloses: Consultancy fees from Amgen, AstraZeneca, Black Diamond Therapeutics, Blueprint Medicines, Cullinan Therapeutics, Daiichi Sankyo, Janssen Pharmaceuticals, Novocure, Taiho Pharmaceuticals and Takeda. Grants/research support from Black Diamond Therapeutics, Blueprint Medicines, Cullinan Therapeutics, Daiichi Sankyo, Erasca, Janssen Pharmaceuticals, Pfizer and SystImmune (all funds paid to medical institution).
Dr Antonio Passaro discloses: Consultancy fees from Bayer and Johnson & Johnson (Janssen Pharmaceuticals). Advisory board or panel fees from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, GSK, Johnson & Johnson (Janssen Pharmaceuticals), Merck Sharp and Dohme, MundiPharma, Novartis, Pfizer and Roche.
Content Reviewer
Danielle Walker, APRN has no financial interests/relationships or affiliations in relation to this activity.
Touch Medical Contributors
Kathy Day has no financial interests/relationships or affiliations in relation to this activity.
Rebecca Franklin discloses: Independent contractor relationships with Fishawack Communications (relationship terminated).
USF Health Office of Continuing Professional Development and touchIME staff have no financial interests/relationships or affiliations in relation to this activity.
Requirements for Successful Completion
In order to receive credit for this activity, participants must review the content and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.
If you have questions regarding credit please contact cpdsupport@usf.edu.
Accreditations
Physicians
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and touchIME. USF Health is accredited by the ACCME to provide continuing medical education for physicians.
USF Health designates this enduring Module 1 activity for a maximum of 0.5Ā AMA PRA Category 1 CreditTM.Ā Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS) ā European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTMĀ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
Advanced Practice Providers
Physician Assistants may claim a maximum of 0.5 Category 1 credits for completing this module. NCCPA accepts AMA PRA Category 1 CreditTMĀ from organizations accredited by ACCME or a recognized state medical society.
The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTMĀ by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.
Nurses
USF Health is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Centerās Commission on Accreditation.
A maximum of 0.5 contact hours may be earned by learners who successfully complete this continuing nursing education module. USF Health, the accredited provider, acknowledges touchIME as the joint provider in the planning and execution of this CNE module.
This module is awarded 0.5 ANCC pharmacotherapeutic contact hours.
Date of original release: 26 September 2024. Date credits expire: 26 September 2025.
If you have any questions regarding credit please contact cpdsupport@usf.edu.
EBACĀ® Accreditation
touchIME is an EBACĀ® accredited provider since 2023.
This module is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBACĀ®) for 0.5 hours of effective education time.
The Accreditation Council for Continuing Medical Education (ACCMEĀ®), and the Royal College of Physicians and Surgeons of Canada hold an agreement on mutual recognition on substantive equivalency of accreditation systems with EBACĀ®.
Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionals and the American Medical Association (AMA), physicians may convert EBACĀ® CE credits to AMA PRA Category 1 CreditsTM. Information on the process to convert EBACĀ® credit to AMA credit can be found on the AMA website. Other healthcare professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 CreditTM.
Faculty Disclosure Statement / Conflict of Interest Policy
In compliance with EBACĀ® guidelines, all speakers/ chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organizing Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event have been mitigated and declared to the audience prior to the CME activities.
Requirements for Successful Completion
Certificates of Completion may be awarded upon successful completion of the post-test and evaluation form. If you have completed one hour or more of effective education through EBACĀ® accredited CE activities, please contact us at accreditation@touchime.org to receive your EBACĀ® CE credit certificate. EBACĀ® grants 1 CE credit for every hour of education completed.
Time to complete Module 1: 0.5 hours
If you have any questions regarding the EBACĀ® credits, please contact accreditation@touchime.org
-
PART 2 of 9 Skip to Modules
- Time: 09:37
Part 2 ć¼EGFR-mutant NSCLC: Evaluating the latest advances in therapeutic strategies
Dr Antonio Passaro, an oncologist specializing in lung cancer, provides insights into the latest advances in therapeutic strategies for EGFR-mutant metastatic non-small cell lung cancer (NSCLC), focusing on recent clinical trial data in both the first- and second-line settings.
After watching this activity, participants should be better able to:
- Recall the latest clinical trial data for first- and second-line treatment options in patients with EGFR-mutant and wildtype NSCLC and their implications for treatment sequencing.
This activity is jointly provided by USF Health and touchIME. read more
Target Audience
This activity has been designed to meet the educational needs of oncologists, including lung cancer specialists, pulmonologists, pathologists and oncology nurses involved in the management of patients with NSCLC.
Disclosures
USF Health adheres to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant relationships are listed below. All individuals not listed have no relevant financial relationships.
Faculty
Dr Helena Yu discloses: Consultancy fees from Amgen, AstraZeneca, Black Diamond Therapeutics, Blueprint Medicines, Cullinan Therapeutics, Daiichi Sankyo, Janssen Pharmaceuticals, Novocure, Taiho Pharmaceuticals and Takeda. Grants/research support from Black Diamond Therapeutics, Blueprint Medicines, Cullinan Therapeutics, Daiichi Sankyo, Erasca, Janssen Pharmaceuticals, Pfizer and SystImmune (all funds paid to medical institution).
Dr Antonio Passaro discloses: Consultancy fees from Bayer and Johnson & Johnson (Janssen Pharmaceuticals). Advisory board or panel fees from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, GSK, Johnson & Johnson (Janssen Pharmaceuticals), Merck Sharp and Dohme, MundiPharma, Novartis, Pfizer and Roche.
Content Reviewer
Danielle Walker, APRN has no financial interests/relationships or affiliations in relation to this activity.
Touch Medical Contributors
Kathy Day has no financial interests/relationships or affiliations in relation to this activity.
Rebecca Franklin discloses: Independent contractor relationships with Fishawack Communications (relationship terminated).
USF Health Office of Continuing Professional Development and touchIME staff have no financial interests/relationships or affiliations in relation to this activity.
Requirements for Successful Completion
In order to receive credit for this activity, participants must review the content and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.
If you have questions regarding credit please contact cpdsupport@usf.edu.
Accreditations
Physicians
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and touchIME. USF Health is accredited by the ACCME to provide continuing medical education for physicians.
USF Health designates this enduringĀ Module 1 activity for a maximum of 0.5Ā AMA PRA Category 1 CreditTM.Ā Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS) ā European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTMĀ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
Advanced Practice Providers
Physician Assistants may claim a maximum of 0.5 Category 1 credits for completing this module. NCCPA accepts AMA PRA Category 1 CreditTMĀ from organizations accredited by ACCME or a recognized state medical society.
The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTMĀ by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.
Nurses
USF Health is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Centerās Commission on Accreditation.
A maximum of 0.5 contact hours may be earned by learners who successfully complete this continuing nursing education module. USF Health, the accredited provider, acknowledges touchIME as the joint provider in the planning and execution of this CNE module.
This module is awarded 0.5 ANCC pharmacotherapeutic contact hours.
Date of original release: 26 September 2024. Date credits expire: 26 September 2025.
If you have any questions regarding credit please contact cpdsupport@usf.edu.
EBACĀ® Accreditation
touchIME is an EBACĀ® accredited provider since 2023.
This module is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBACĀ®) for 0.5 hours of effective education time.
The Accreditation Council for Continuing Medical Education (ACCMEĀ®), and the Royal College of Physicians and Surgeons of Canada hold an agreement on mutual recognition on substantive equivalency of accreditation systems with EBACĀ®.
Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionals and the American Medical Association (AMA), physicians may convert EBACĀ® CE credits to AMA PRA Category 1 CreditsTM. Information on the process to convert EBACĀ® credit to AMA credit can be found on the AMA website. Other healthcare professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 CreditTM.
Faculty Disclosure Statement / Conflict of Interest Policy
In compliance with EBACĀ® guidelines, all speakers/ chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organizing Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event have been mitigated and declared to the audience prior to the CME activities.
Requirements for Successful Completion
Certificates of Completion may be awarded upon successful completion of the post-test and evaluation form. If you have completed one hour or more of effective education through EBACĀ® accredited CE activities, please contact us at accreditation@touchime.org to receive your EBACĀ® CE credit certificate. EBACĀ® grants 1 CE credit for every hour of education completed.
Time to Complete Module 1: 0.5 hours
If you have any questions regarding the EBACĀ® credits, please contact accreditation@touchime.org
-
PART 3 of 9 Skip to Modules
- Time: 13:22
Part 3 ć¼EGFR-mutant NSCLC: Practical insights and implications for NSCLC practice
Dr Helena Yu provides an overview of the current treatment options for EGFR-mutant metastatic non-small cell lung cancer (NSCLC). She uses a patient case to explore both the existing therapies available at diagnosis and at the point of disease progression, as well as how ongoing research and the advent of new therapies and combination strategies might impact future treatment approaches.
After watching this activity, participants should be better able to:
- Recall the latest clinical trial data for first- and second-line treatment options in patients with EGFR-mutant and wildtype NSCLC and their implications for treatment sequencing.
- Use knowledge of efficacy and safety data for current and emerging first- and second-line treatments in patients with EGFR-mutant and wildtype NSCLC to develop optimal care pathways and improved clinical outcomes.
This activity is jointly provided by USF Health and touchIME. read more
Target Audience
This activity has been designed to meet the educational needs of oncologists, including lung cancer specialists, pulmonologists, pathologists and oncology nurses involved in the management of patients with NSCLC.
Disclosures
USF Health adheres to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant relationships are listed below. All individuals not listed have no relevant financial relationships.
Faculty
Dr Helena Yu discloses: Consultancy fees from Amgen, AstraZeneca, Black Diamond Therapeutics, Blueprint Medicines, Cullinan Therapeutics, Daiichi Sankyo, Janssen Pharmaceuticals, Novocure, Taiho Pharmaceuticals and Takeda. Grants/research support from Black Diamond Therapeutics, Blueprint Medicines, Cullinan Therapeutics, Daiichi Sankyo, Erasca, Janssen Pharmaceuticals, Pfizer and SystImmune (all funds paid to medical institution).
Dr Antonio Passaro discloses: Consultancy fees from Bayer and Johnson & Johnson (Janssen Pharmaceuticals). Advisory board or panel fees from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, GSK, Johnson & Johnson (Janssen Pharmaceuticals), Merck Sharp and Dohme, MundiPharma, Novartis, Pfizer and Roche.
Content Reviewer
Danielle Walker, APRN has no financial interests/relationships or affiliations in relation to this activity.
Touch Medical Contributors
Kathy Day has no financial interests/relationships or affiliations in relation to this activity.
Rebecca Franklin discloses: Independent contractor relationships with Fishawack Communications (relationship terminated).
USF Health Office of Continuing Professional Development and touchIME staff have no financial interests/relationships or affiliations in relation to this activity.
Requirements for Successful Completion
In order to receive credit for this activity, participants must review the content and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.
If you have questions regarding credit please contact cpdsupport@usf.edu.
Accreditations
Physicians
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and touchIME. USF Health is accredited by the ACCME to provide continuing medical education for physicians.
USF Health designates this enduringĀ Module 1 activity for a maximum of 0.5Ā AMA PRA Category 1 CreditTM.Ā Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS) ā European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTMĀ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
Advanced Practice Providers
Physician Assistants may claim a maximum of 0.5 Category 1 credits for completing this module. NCCPA accepts AMA PRA Category 1 CreditTMĀ from organizations accredited by ACCME or a recognized state medical society.
The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTMĀ by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.
Nurses
USF Health is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Centerās Commission on Accreditation.
A maximum of 0.5 contact hours may be earned by learners who successfully complete this continuing nursing education module. USF Health, the accredited provider, acknowledges touchIME as the joint provider in the planning and execution of this CNE module.
This module is awarded 0.5 ANCC pharmacotherapeutic contact hours.
Date of original release: 26 September 2024. Date credits expire: 26 September 2025.
If you have any questions regarding credit please contact cpdsupport@usf.edu.
EBACĀ® Accreditation
touchIME is an EBACĀ® accredited provider since 2023.
This module is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBACĀ®) for 0.5 hours of effective education time.
The Accreditation Council for Continuing Medical Education (ACCMEĀ®), and the Royal College of Physicians and Surgeons of Canada hold an agreement on mutual recognition on substantive equivalency of accreditation systems with EBACĀ®.
Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionals and the American Medical Association (AMA), physicians may convert EBACĀ® CE credits to AMA PRA Category 1 CreditsTM. Information on the process to convert EBACĀ® credit to AMA credit can be found on the AMA website. Other healthcare professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 CreditTM.
Faculty Disclosure Statement / Conflict of Interest Policy
In compliance with EBACĀ® guidelines, all speakers/ chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organizing Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event have been mitigated and declared to the audience prior to the CME activities.
Requirements for Successful Completion
Certificates of Completion may be awarded upon successful completion of the post-test and evaluation form. If you have completed one hour or more of effective education through EBACĀ® accredited CE activities, please contact us at accreditation@touchime.org to receive your EBACĀ® CE credit certificate. EBACĀ® grants 1 CE credit for every hour of education completed.
Time to Complete Module 1: 0.5 hours
If you have any questions regarding the EBACĀ® credits, please contact accreditation@touchime.org
Modules
Time: 09:37
Module 1 ā Part 2:
EGFR-mutant NSCLC: Evaluating the latest advances in therapeutic strategies
Time: 13:22
Module 1 ā Part 3:
EGFR-mutant NSCLC: Practical insights and implications for NSCLC practice
Coming Soon
Module 2 - Part 1:
Advances in the treatment landscape for EGFR-wildtype NSCLC
Coming Soon
Module 2 - Part 2:
Insights from the latest data and strategies for improvement
Coming Soon
Module 2 - Part 3:
Practical insights and implications for NSCLC practice
Coming Soon
Module 3 - Part 1:
Novel strategies, care pathways and side effect management
Coming Soon
Module 3 - Part 2:
Implications of novel treatments on the shifting biomarker landscape
Coming Soon
Module 3 - Part 3:
Optimizing outcomes in late-stage NSCLC: Key learnings
You may also be interested in...
touchPANEL DISCUSSION
Expanding HER2 horizons: Implications for NSCLC and beyond
This activity is CE/CME accreditedtouchEXPERT OPINIONS
Immunotherapy for early-stage, resectable NSCLC: From clinical trial data to guidelines
This activity is CE/CME accreditedCONFERENCE HUB
Paulo Rodrigues Santos, ERS 2022: Immunosuppressive Factors Affecting Anti-PD-1 Therapy in Phase IIIB/IV Non-small Cell Lung Cancer
CONFERENCE HUB
Rolof Gijtenbeek, ERS 2021: The NVALT 17 Study
JOURNALS
The Use of Sweetened and Flavored Electronic Cigarettes Among Young Peopleāa Growing Concern
JOURNALS
Endobronchial Involvement in Sarcoidosis
Topics covered in this activity
Lung Cancer / Thoracic OncologyREGISTER NOW FOR FREE ACCESS TO
- 1000+ topical and insightful peer-reviewed journal articles
- 1000+ topical and insightful peer-reviewed journal articles
- 10 major therapy areas packed with the latest scientific advances
- 150+ specialties offering learn-on-the-go medical education
- + Concise email updates and newsletters so you never miss out
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORY
Sign me up!Got 2 minutes?
Your feedback is important to us
1 = strongly disagree; 5 = strongly agree* = Mandatory Field